Table 1.
Comparison of half-maximal inhibition concentrations (IC50) for particular cell lines, cytostatics and used assay. S.E., standard error. Differences were considered significant, when p < 0.05. * Significantly different from doxorubicin (Analysis of variance (ANOVA) followed by Bonferroni post hoc testing) † Significantly different from epirubicin (ANOVA followed by Bonferroni post hoc testing) ‡ Significantly different from lip-8-dox (ANOVA followed by Bonferroni post hoc testing) § Significantly different from apodox (ANOVA followed by Bonferroni post hoc testing) ‖ Significantly different from myocet (ANOVA followed by Bonferroni post hoc testing) $ Significantly different from MTT (ANOVA followed by Bonferroni post hoc testing).
| Factor | Level of Factor | N | IC50 (Mean ± S.E.) | Significant Difference (At p < 0.05) |
|---|---|---|---|---|
| Cytostatic F(4, 68) = 20.49, p < 0.0001 | Epirubicin | 21 | 118.0 ± 27.2 | ‡, §, ‖ |
| Doxorubicin | 18 | 268.9 ± 43.6 | §, ‖ | |
| Apodox | 22 | 1095.0 ± 163.8 | *, †, ‖ | |
| Lip-8 | 16 | 1014.5 ± 209.8 | †, ‖ | |
| Myocet | 21 | 1915.4 ± 417.3 | *, †, ‡, § | |
| Cell line F(2, 68) = 0.46, p = 0.47 | PNT1A | 36 | 936.3 ± 167.9 | |
| 22RV1 | 32 | 834.5 ± 161.5 | ||
| LNCaP | 30 | 915.1 ± 299.6 | ||
| Method F(1, 68) = 6.48, p < 0.013 | MTT | 31 | 1200.1 ± 316.1 | |
| RTCA | 67 | 756.1 ± 98.1 | $ |